Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174349 · ClinicalTrials.gov registry record · Phase 4
Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery
A Phase 4 study of Urinary Retention Postoperative, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07174349 is a Phase 4 study of Urinary Retention Postoperative that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 23,453-participant average among 3 other Urinary Retention Postoperative trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07174349, a Phase 4 study of Urinary Retention Postoperative, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Uroselective alpha-1-adrenergic receptor antagonist
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174349
The ClinicalTrials.gov registry entry for NCT07174349 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 23,453-participant average among 3 other Urinary Retention Postoperative trials with a reported enrollment target (100% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Retention Postoperative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07174349 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07174349 about?
NCT07174349 is a clinical study titled "Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery". The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.
What is the current status of trial NCT07174349?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-02-01. Estimated completion is 2028-12-31.
What conditions does trial NCT07174349 study?
This clinical trial studies the following conditions: Urinary Retention Postoperative.
What interventions are being tested in trial NCT07174349?
The interventions under investigation include: Placebo (OTHER), Uroselective alpha-1-adrenergic receptor antagonist (DRUG).
Who is sponsoring clinical trial NCT07174349?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174349 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Retention Postoperative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
RECRUITING · Phase 2
-
NMBA Reversal and Postoperative Urinary Retention
ACTIVE NOT RECRUITING
-
Strict Need to Void After Same-day Discharge, Non-urogynecologic, Minimally Invasive Hysterectomy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.